Skip to primary navigation
Skip to main content
Skip to primary navigation
Skip to main content
Toggle Search
Search
Choose which site to search.
Current site
All of UAMS
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller
Cancer Institute
UAMS Health
Jobs
Giving
Toggle Search
Toggle Primary Nav
About
From the Director
Our History
Leadership
Board of Advisors
Health Equity and Workforce Development
About Little Rock
Maps & Directions
Cancer Institute Magazine
News
College of Medicine
Patient Care
Clinical Trials
Research
Research Programs
Membership
Clinical Research
Funding Opportunities
Shared Resources
Training and Education
Get Involved
Donate
Fundraising Events
Volunteer Services & Auxiliary
The Envoys
Contact
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
Recurring
Tags:
Recurring
NCT05544032 – An Open-Label, Expanded Access Program of Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease in Participants Who Have Received at Least 2 Lines of Systemic Therapy
NCT05090566 – MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma
NCT05169580 – A Phase 1 Open-Label, Multiple Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)
NCT04929041 – A082002 – A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer
NCT05624996 – NRG-LU008: Phase III Prospective Randomized Trial OfPrimary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
NCT06433219 – An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD)-positive epithelial ovarian cancer that progressed on prior PARP inhibitor therapy
NCT00969111 – GU010-18 Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT06203600 – S2303, Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel +Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
NCT05610163 – A022104, The Janus Rectal Cancer Trial: A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer
NCT05169580 – A Phase 1 Open-Label, Multiple Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)
1
2
3
…
5
Next